Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment

Core Insights - Paris Hilton collaborates with Collegium Pharmaceutical to share her ADHD journey and encourage others to seek treatment [3][5][6] - ADHD affects approximately 15.5 million adults and 6.5 million children in the U.S., with an estimated 70% of adults experiencing symptoms into adulthood [4] Company Overview - Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company focused on improving the lives of individuals with serious medical conditions, particularly in pain management and neuropsychiatry [16][17] - The company’s leading product, JORNAY PM, is a treatment for ADHD that is taken at night and lasts throughout the day [6][7] Product Information - JORNAY PM is indicated for the treatment of ADHD in patients aged 6 years and older, helping to increase attention and decrease impulsiveness and hyperactivity [7] - The medication contains methylphenidate and is classified as a federally controlled substance due to its potential for abuse [8][9] Treatment Journey - Paris Hilton was diagnosed with ADHD as a young adult and has since worked with her healthcare provider to find an effective treatment plan, ultimately choosing JORNAY PM [6][5] - The collaboration aims to raise awareness about ADHD and the importance of finding suitable treatment options [3][5]